Theranostics 2022; 12(1):421. doi:10.7150/thno.68830 This issue Cite

Erratum

Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum

Haoran Liu1,2*, Xiaoqi Yang1*, Kun Tang1, Tao Ye1, Chen Duan1, Peng Lv1, Libin Yan1, Xiaoliang Wu1, Zhiqiang Chen1, Jianhe Liu2, Yaoliang Deng3, Guohua Zeng4, Jinchun Xing5, Zhangqun Ye1, Hua Xu1 Corresponding address

1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
3. Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
4. Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
5. Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
*These authors contributed equally to this work.

Citation:
Liu H, Yang X, Tang K, Ye T, Duan C, Lv P, Yan L, Wu X, Chen Z, Liu J, Deng Y, Zeng G, Xing J, Ye Z, Xu H. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics 2022; 12(1):421. doi:10.7150/thno.68830. https://www.thno.org/v12p0421.htm
Other styles

File import instruction

Corrected-article in Theranostics, Volume 10, 7319

 

The authors apologize for the original version of our paper unfortunately contained an incorrect representative image of immunohistochemical (IHC) staining for IRF1. Noting that 200x IHC images in the first submitted version were correct. For presenting high resolution images according to one of the reviewer's suggestion, we assembled 400x IHC images in our revised manuscript. IHC staining for IRF1 in the group of Gly + SFN 25 mg/kg was misused as Gly + SFN 50 mg/kg. We apologize that at the time of figure assembly, we choose representative images by mistake. We apologize for our careless at the time of figure assembly. We confirm that it would not affect any results and conclusions of the paper. The correct representative images for Figure 2A are shown below. The authors apologize for any inconvenience that this error may have caused.

 Figure 1 

Corrected image for original Figure 2A.

Theranostics Image

Author contact

Corresponding address Corresponding author: Prof. Hua Xu, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. E-mail: xuhuaedu.cn.


Published 2022-1-1


Citation styles

APA
Liu, H., Yang, X., Tang, K., Ye, T., Duan, C., Lv, P., Yan, L., Wu, X., Chen, Z., Liu, J., Deng, Y., Zeng, G., Xing, J., Ye, Z., Xu, H. (2022). Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics, 12(1), 421. https://doi.org/10.7150/thno.68830.

ACS
Liu, H.; Yang, X.; Tang, K.; Ye, T.; Duan, C.; Lv, P.; Yan, L.; Wu, X.; Chen, Z.; Liu, J.; Deng, Y.; Zeng, G.; Xing, J.; Ye, Z.; Xu, H. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics 2022, 12 (1), 421. DOI: 10.7150/thno.68830.

NLM
Liu H, Yang X, Tang K, Ye T, Duan C, Lv P, Yan L, Wu X, Chen Z, Liu J, Deng Y, Zeng G, Xing J, Ye Z, Xu H. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics 2022; 12(1):421. doi:10.7150/thno.68830. https://www.thno.org/v12p0421.htm

CSE
Liu H, Yang X, Tang K, Ye T, Duan C, Lv P, Yan L, Wu X, Chen Z, Liu J, Deng Y, Zeng G, Xing J, Ye Z, Xu H. 2022. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics. 12(1):421.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image